Related Experiment Video
Updated: Aug 11, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Secondary prevention trials after myocardial infarction
1Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27103.
Beta-blockers without intrinsic sympathomimetic activity (ISA) improve long-term survival after myocardial infarction. Platelet-active drugs reduce reinfarctions, but other treatments show no clear survival benefits.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Secondary prevention after myocardial infarction (MI) is crucial for improving patient outcomes.
- Numerous clinical trials have investigated various pharmacological interventions post-MI.
Purpose of the Study:
- To compare and review secondary prevention trials following myocardial infarction.
- To evaluate the efficacy of different drug classes on long-term survival and reinfarction rates.
Main Methods:
- Systematic review and meta-analysis of existing secondary prevention trials.
- Comparative analysis of treatment effects across different drug categories.
Main Results:
- Beta-blockers, especially those without intrinsic sympathomimetic activity (ISA), significantly improve long-term survival post-MI.
- Platelet-active medications reduce reinfarction rates and may offer survival benefits.
- Lipid-lowering drugs, anticoagulants, calcium channel blockers, and antiarrhythmics have not demonstrated convincing survival benefits.
Conclusions:
- Beta-blockers and platelet-active drugs are key in secondary MI prevention.
- Current evidence does not support the routine use of lipid-lowering regimens, anticoagulants, calcium channel blockers, or antiarrhythmics for improving survival post-MI.
- Challenges in subgroup analysis and statistical evaluation of treatment effects warrant further investigation.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care